Mirabegron and Physiological Function in Cold Environments
Mirabegron and Physiological Function in Cold Environments
スポンサー |
リードスポンサー: Indiana University |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ソース | Indiana University | ||||||||||||||||||||||||||||||
簡単な要約 | Many Navy diving operations are performed in cold water. Despite technical advances to improve thermal protection for cold water diving, these applications are cumbersome and do not provide complete thermal protection as thermal discomfort is subjectively reported by many Navy divers. Brown adipose tissue is highly thermogenic in humans. Therefore, activation of brown adipose tissue might improve cold water tolerance and lower thermal discomfort during cold water diving operations. Mirabegron is a beta-3-adrenergic receptor agonist that is used to treat overactive bladder. Beta-3-adrenergic receptors are located on the urinary bladder, gallbladder and brown adipose tissue. Recent evidence has demonstrated that acute mirabegron administration increases thermogenesis for ~3 hours in humans. However, it is currently not known which dose of mirabegron can increase thermogenesis for longer durations. It is also not known if mirabegron administration can improve cold water tolerance and thermal discomfort during cold water immersion. Finally, it is not known if mirabegron can increase thermogenesis during sympathetic stimulation. This project will fill these knowledge gaps by addressing these specific aims: 1) determine which dose of mirabegron administration will increase thermogenesis during 6 hours of a mild cold stress challenge, 2) determine if acute mirabegron administration will delay the fall in core temperature and the onset of shivering during a progressive cold-water immersion challenge, and 3) compare the dose of isoproterenol required to evoke a thermogenic response equal to a 15% increase above rest, following ingestion of either mirabegron or a placebo. In addition to filling these knowledge gaps, the activation of brown adipose tissue by mirabegron might be influenced by the gut microbiome. Therefore, the association between the gut microbiome and mirabegron metabolism will be explored. Collectively, these studies will show if mirabegron is a potential ergogenic aid that can be used to improve cold water tolerance in Navy divers which will ultimately improve the likelihood of successful missions. |
||||||||||||||||||||||||||||||
全体的なステータス | Not yet recruiting | ||||||||||||||||||||||||||||||
開始日 | May 2021 | ||||||||||||||||||||||||||||||
完成日 | May 2023 | ||||||||||||||||||||||||||||||
一次完成日 | May 2023 | ||||||||||||||||||||||||||||||
段階 | Phase 1/Phase 2 | ||||||||||||||||||||||||||||||
研究の種類 | Interventional | ||||||||||||||||||||||||||||||
主な結果 |
|
||||||||||||||||||||||||||||||
二次転帰 |
|
||||||||||||||||||||||||||||||
入学 | 30 | ||||||||||||||||||||||||||||||
状態 | |||||||||||||||||||||||||||||||
介入 |
介入タイプ: Drug 介入名: Mirabegron 説明文: Dose-response effect on thermogenesis |
||||||||||||||||||||||||||||||
適格性 |
基準:
Inclusion Criteria: - Men and women - 18-40 years old - Participate in 150 minutes or more of at least moderate intensity exercise per week during the previous 2 years Exclusion Criteria: - diagnosed autonomic disease - diagnosed cardiovascular disease - diagnosed metabolic disease - diagnosed neurologic disease - diagnosed endocrine disease - diagnosed respiratory disease - diagnosed liver dysfunction - diagnosed kidney dysfunction - Women who are pregnant or breastfeeding - Individuals currently taking a medication (with the exception of birth control, including hormonal contraception) that cannot be safely discontinued for 5 biological half-lifes prior to each study visit based on consultation with the study physician. - Current tobacco or electronic cigarette use or consistent use within the last 1 year 性別: All 最低年齢: 18 Years 最大年齢: 40 Years 健康なボランティア: Accepts Healthy Volunteers |
||||||||||||||||||||||||||||||
全体的な公式 |
|
||||||||||||||||||||||||||||||
全体的な連絡先 |
苗字: Blair D Johnson, PhD 電話: 8128558699 Eメール: [email protected] |
||||||||||||||||||||||||||||||
確認日 |
February 2021 |
||||||||||||||||||||||||||||||
責任者 |
タイプ: Principal Investigator 調査官の所属: Indiana University 調査官の氏名: Blair D. Johnson 調査官の肩書: Associate Professor School of Public Health |
||||||||||||||||||||||||||||||
アクセスを拡大しました | No | ||||||||||||||||||||||||||||||
腕の数 | 4 | ||||||||||||||||||||||||||||||
アームグループ |
ラベル: Placebo タイプ: Placebo Comparator 説明文: Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room ラベル: 100 mg Mirabegron タイプ: Experimental 説明文: Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room ラベル: 150 mg Mirabegron タイプ: Experimental 説明文: Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room ラベル: 200 mg Mirabegron タイプ: Experimental 説明文: Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room |
||||||||||||||||||||||||||||||
患者データ | No | ||||||||||||||||||||||||||||||
研究デザイン情報 |
割り当て: Randomized 介入モデル: Crossover Assignment 主な目的: Basic Science マスキング: Double (Participant, Investigator) |
Clinical Research News
- Apr 19
- Apr 16
- Apr 14
- Apr 14
- Apr 14
- Apr 14
- Apr 14
- Apr 14
- Apr 14
- Apr 13